Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 13;189(10):E398-E404.
doi: 10.1503/cmaj.160771.

Principles of diagnosis and management of neuroendocrine tumours

Michael J Raphael  1 , David L Chan  1 , Calvin Law  1 , Simron Singh  2
Affiliations
Review

Principles of diagnosis and management of neuroendocrine tumours

Michael J Raphael et al. CMAJ. .
No abstract available

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Pathology specimens of tissue from a neuroendicrine tumour with staining for Ki67 (a nuclear protein involved with cell proliferation). MIB-1 is an immunoglobulin G (IgG) antibody directed against Ki67 that can be used to identify the percentage of cells undergoing active cell proliferation. (A) Ki67 index < 3%. (B) Ki67 index 3%–20%. (C) Ki67 index > 20%. Images provided by Dr. Corwyn Rowsell (St. Michael’s Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ont.).
Figure 2:
Figure 2:
Comparison of 68Ga-DOTATATE PET/CT and 18FDG PET/CT for detection of poorly and well-differentiated neuroendocrine tumours. 68Gallium radiolabelled somatostatin analogue PET/CT is more sensitive for identifying well-differentiated tumours in which the somatostatin receptor expression is preserved on neuroendocrine cells. 18FDG PET/CT is more sensitive for identifying poorly differentiated tumours in which the somatostatin receptor expression has been lost. Please note that the comparison images are from from different patients to illustrate differences in detail by modality based on the differentiation of the tumour. Images provided by Dr. David Chan (Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.). FDG = fluorodeoxyglucose, PET/CT = positron emission tomography–computed tomography.
See this image and copyright information in PMC

References

    1. Hallet J, Law CHL, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015;121:589–97. - PubMed
    1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2015. Toronto: Canadian Cancer Society; 2015.
    1. Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol 2016. Oct. 28 [Epub ahead of print]. 10.1200/JGO.2015.002980. - DOI - PMC - PubMed
    1. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72. - PubMed
    1. Pape UF, Berndt U, Muller-Nordhorn J. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2008;15: 1083–97. - PubMed

MeSH terms